> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-030.md).
# BRE 030
**AM RF EMF, CACNA1H Calcium Channels, and Breast Cancer Brain Metastasis**
**Clinical Cancer Name:** Breast Carcinoma With Brain Metastasis\
**Common Cancer Name:** Breast Cancer That Has Spread to the Brain
## Source
Sharma, S., Wu, S., Jimenez, H., et al. (2019).\
*Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF.*\
*EBioMedicine*, 44, 194–208.
***
## BRS Score
**BRS:** 9.2 / 10\
**STEMD:** S9 / T9 / E9 / M10 / D9\
**External Evidence Level:** Moderate–High experimental and translational evidence
## Score Interpretation
BRE-030 receives one of the strongest BRS scores so far because it includes in-vitro models, in-vivo animal models, patient-derived xenografts, mechanistic molecular analysis, and a compassionate clinical case. It also provides a specific pathway: AM RF EMF may act through CACNA1H/CaV3.2 calcium-channel activation and downstream tumor-suppressive signaling.
***
## Entry Summary
BRE-030 asks a major treatment-direction question:
Can a breast-cancer-specific electromagnetic signal suppress breast cancer brain metastasis through calcium-channel signaling?
This study focused on amplitude-modulated radiofrequency electromagnetic fields, not TTFields.
The exposure system used a 27.12 MHz carrier frequency with breast-cancer-specific amplitude modulation. The extraction identifies this as a nonthermal / athermal exposure model with in-vitro, in-vivo, patient-derived xenograft, and compassionate-use clinical application evidence.
In simple language:
This study suggests that certain carefully designed electromagnetic signals may interact with specific calcium channels on breast cancer cells and reduce metastatic behavior.
***
## What BREXAtlas Found
BREXAtlas identifies this primary mechanism chain:
AM RF EMF\
↓\
CACNA1H / CaV3.2 T-type calcium-channel activation\
↓\
Calcium influx\
↓\
CAMKII activation\
↓\
p38 MAPK signaling\
↓\
β-catenin / HMGA2 suppression\
↓\
Cancer stem cell suppression\
↓\
Reduced brain metastatic growth
A secondary mechanism chain is:
AM RF EMF\
↓\
Reduced exosomal miR-1246\
↓\
Reduced angiogenic signaling\
↓\
Altered brain metastatic microenvironment\
↓\
Reduced metastatic support
This makes BRE-030 one of the most important entries in the encyclopedia because it shows a specific electromagnetic-to-biological signaling pathway rather than a broad nonspecific EMF claim.
***
## Questions This BRE Helps Answer
What is AM RF EMF?
AM RF EMF means amplitude-modulated radiofrequency electromagnetic field.
This is different from TTFields and different from environmental EMF exposure.
What BREXAtlas found:\
BRE-030 studied a targeted breast-cancer-specific AM RF EMF system using a 27.12 MHz carrier frequency and amplitude-modulated breast-cancer-specific frequencies.
What is CACNA1H?
CACNA1H is a gene that encodes the CaV3.2 T-type calcium channel.
Calcium channels help control calcium movement into cells.
What BREXAtlas found:\
BRE-030 supports that CACNA1H/CaV3.2 may mediate the response to AM RF EMF in breast cancer brain metastasis models.
Why does calcium matter?
Calcium is a powerful signaling molecule.
When calcium movement changes, cancer-cell behavior can change.
What BREXAtlas found:\
BRE-030 connects AM RF EMF exposure to calcium influx, CAMKII activation, p38 MAPK signaling, and suppression of pathways linked to metastatic behavior.
Why does this matter for people affected by breast cancer?
Brain metastasis is one of the most serious and frightening complications of breast cancer.
BRE-030 does not prove a standard clinical treatment.
But it does show that breast cancer brain metastasis may have a measurable electromagnetic-calcium vulnerability worth studying carefully.
***
## Study Classification
| Category | Classification |
| ---------------------------------------- | ----------------------------------------------------------------- |
| Study Type | Experimental + translational + compassionate clinical case |
| Tissue Category | Breast cancer; brain metastasis |
| Common Cancer Name | Breast cancer that has spread to the brain |
| Subtypes / Models | Triple-negative breast cancer; HER2-positive breast cancer models |
| Exposure Type | Amplitude-modulated RF EMF |
| Carrier Frequency | 27.12 MHz |
| Dosimetry Notes | In-vitro SAR range included 30–400 mW/kg |
| Direct TTFields Evidence | No |
| Direct RF EMF Evidence | Yes |
| Direct Calcium-Channel Evidence | Yes |
| Suitable for Frequency Index | Yes |
| Suitable for Calcium / Ion-Channel Index | Yes |
| Suitable for Metastasis Index | Yes |
| Suitable for Translation Index | Yes |
***
## Cell Lines / Models
BRE-030 identified:
* SKBrM3
* 231-BrM
* MDA-MB-231
* SKBR3
* T47D
* BT-474
* MDA-MB-453
* Patient-derived xenografts
* Breast cancer brain metastasis patient case
These models make BRE-030 especially important because it spans multiple breast cancer systems, including brain metastasis models.
***
## Mechanisms
**MEC-027: Voltage-Gated Ion Channel Activation**
BRE-030 supports voltage-gated calcium-channel activation as a central electromagnetic-response mechanism.
**MEC-028: Calcium Overload / Calcium-Driven Cytotoxicity**
Calcium influx appears central to the observed tumor-suppressive response.
**MEC-030: Ion-Channel Oncogenic Signaling**
Ion-channel signaling may regulate tumor behavior and metastatic potential.
**MEC-035: CACNA1H Electromagnetic Antenna Signaling**
CACNA1H / CaV3.2 T-type calcium channels may function as electromagnetic-responsive mediators that translate AM RF EMF exposure into calcium influx and downstream tumor-suppressive signaling.
**MEC-036: Bioelectric Cancer Stem Cell Suppression**
Electromagnetic calcium-channel activation may suppress cancer stem cell traits through CAMKII / β-catenin / HMGA2 signaling changes.
**MEC-037: Exosomal Electromagnetic Signaling Modulation**
AM RF EMF exposure may alter exosomal miRNA signaling, including miR-1246, and reduce angiogenic or microenvironmental support for metastasis.
***
## Discoveries
**DISC-012: Calcium-Driven Tumor Vulnerability**
BRE-030 strongly supports the discovery that calcium signaling may be a major vulnerability in breast cancer electromagnetic response.
**DISC-015: Bioelectric Systems Oncology**
BRE-030 supports Bioelectric Systems Oncology because it connects electromagnetic exposure, calcium-channel signaling, metastatic behavior, cancer stem cell traits, exosomes, angiogenesis, and clinical translation.
**DISC-016: Voltage-Gated Calcium Antenna Systems**
BREXAtlas identifies this as a major discovery:
Specific voltage-gated calcium channels may act as biological antenna systems that translate electromagnetic exposure into tumor-relevant signaling changes.
***
## Connections to Other BRE Entries
### Connected to BRE-023
BRE-023 showed that breast cancer cells can display altered membrane-potential and ion-channel behavior.
BRE-030 identifies a specific ion-channel pathway, CACNA1H/CaV3.2, that may mediate an electromagnetic response.
### Connected to BRE-024
BRE-024 connected electromagnetic exposure with calcium signaling disruption, ROS generation, and mitochondrial stress in T47D breast cancer cells.
BRE-030 expands the calcium pathway into targeted RF EMF, metastasis suppression, and calcium-channel specificity.
### Connected to BRE-026
BRE-026 framed membrane potential and ion-channel signaling as major systems-level drivers of cancer progression.
BRE-030 provides a specific translational example of that systems logic.
### Connected to BRE-025
BRE-025 showed that therapeutic EMF may affect tumor vascularity and angiogenesis.
BRE-030 also includes angiogenesis suppression, but through a different pathway involving exosomal miR-1246 and metastatic microenvironment support.
### Connected to BRE-028 and BRE-029
BRE-028 and BRE-029 are environmental exposure caution entries.
BRE-030 must remain separate from them because it involves a targeted therapeutic-style AM RF EMF system, not uncontrolled environmental exposure.
***
## Research Gaps Identified
**RG-147: CACNA1H Specificity Validation Gap**
The degree to which CACNA1H functions as a reproducible electromagnetic-response mediator across tumor types remains incompletely validated.
**RG-148: AM RF EMF Clinical Translation Gap**
Clinical translation requires larger trials, standardized dosimetry, replication, sham controls, and stronger tissue-specific frequency validation.
**RG-149: Frequency Specificity Gap**
More research is needed to validate which breast-cancer-specific amplitude modulation frequencies produce the most reliable effects.
**RG-150: Brain Metastasis Delivery Gap**
More work is needed to determine how exposure delivery, brain SAR, tumor location, and metastatic burden affect response.
**RG-151: Calcium-Channel Generalization Gap**
It remains unclear whether similar calcium-channel electromagnetic responses occur in other cancer types or only certain breast cancer models.
***
## Scientific Caution
BRE-030 supports a targeted AM RF EMF mechanism involving CACNA1H and calcium signaling, but clinical claims require replication in controlled trials. The findings should not be generalized to all RF or EMF exposures.
***
## Why This Entry Matters
For researchers, BRE-030 is one of the strongest examples of targeted electromagnetic oncology because it links a defined exposure system to a specific calcium-channel mechanism.
For patients and families, the simple idea is this:
Some breast cancers that spread to the brain may have calcium-channel weaknesses. This study suggests a carefully designed electromagnetic signal may affect those channels and reduce metastatic behavior in experimental and early translational models.
This is not proof of a standard treatment. It is strong evidence that the question deserves serious clinical investigation.
***
## Entry Conclusion
BRE-030 begins Batch 3 as a major calcium-channel and metastasis entry.
BRE-023 through BRE-026 established that breast cancer has bioelectric and ion-channel behavior.
BRE-030 identifies a specific electromagnetic pathway involving CACNA1H/CaV3.2, calcium influx, cancer stem cell suppression, exosomal signaling, angiogenesis suppression, and reduced brain metastatic growth.
The central question emerging from this entry is:
Can breast cancer brain metastasis be suppressed by targeting calcium-channel-mediated electromagnetic response pathways?
For BREXAtlas, BRE-030 is a major bridge between bioelectric systems theory, ion-channel biology, metastasis research, and future clinical translation.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-030.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.